{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02828592",
            "orgStudyIdInfo": {
                "id": "NSH 1158"
            },
            "organization": {
                "fullName": "Northside Hospital, Inc.",
                "class": "OTHER"
            },
            "briefTitle": "Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia",
            "officialTitle": "A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor",
            "therapeuticArea": [
                "Other"
            ],
            "study": "haploidentical-bone-marrow-transplant-with-post-transplant-cyclophosphamide-for-patients-with-severe-aplastic-anemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-09-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2016-07-06",
            "studyFirstSubmitQcDate": "2016-07-06",
            "studyFirstPostDateStruct": {
                "date": "2016-07-11",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-04-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Northside Hospital, Inc.",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false
        },
        "descriptionModule": {
            "briefSummary": "Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.",
            "detailedDescription": "Mismatched haploidentical donors will be identified for patients with severe aplastic anemia. These patients will undergo a preparative regimen of Fludarabine/Cyclophosphamide/TBI followed by haploidentical bone marrow transplantation. Post-transplant Cyclophosphamide will be administered on Days 3 \\& 4. Immunosuppression with Tacrolimus and MMF will begin on Day +5; MMF will be discontinued on Day +35 while Tacrolimus continues until Day +180. Investigators hypothesize that haploidentical transplantation with the above-mentioned preparative regimen will have a \\<30% graft failure rate. The one-sided exact Binomial test at 5% significance level will be used to test this hypothesis. The size of 20 patients provides the power of 92.5% for confirming the 30-day graft failure rate \\<30%."
        },
        "conditionsModule": {
            "conditions": [
                "Severe Aplastic Anemia"
            ],
            "keywords": [
                "SAA"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Flu/Cy/TBI",
                    "type": "EXPERIMENTAL",
                    "description": "Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 \\& 4.",
                    "interventionNames": [
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide",
                        "Radiation: Total Body Irradiation",
                        "Drug: Rabbit ATG"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "30 mg/m2 IV QD x 5 days (Days -6 to -2)",
                    "armGroupLabels": [
                        "Flu/Cy/TBI"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "14.5 mg/kg/day IV x 2 doses (Days -6 \\& -5)",
                    "armGroupLabels": [
                        "Flu/Cy/TBI"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Total Body Irradiation",
                    "description": "300 cGy x1 dose (Day -1)",
                    "armGroupLabels": [
                        "Flu/Cy/TBI"
                    ],
                    "otherNames": [
                        "TBI"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rabbit ATG",
                    "description": "1.5 mg/kg/day x 3 days (Days -3 to -1)",
                    "armGroupLabels": [
                        "Flu/Cy/TBI"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Post-transplant: 50 mg/kg IV QD (Day +3 to +4)",
                    "armGroupLabels": [
                        "Flu/Cy/TBI"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Demonstrate sustained engraftment after T-cell replete HLA-mismatched haploidentical bone marrow transplantation by collecting chimerism tests monthly following transplant",
                    "description": "Hypothesis is that following preparative regimen and bone marrow transplantation, the 30-day graft failure rate will be \\<30%.",
                    "timeFrame": "2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Determine the incidence of regimen-related mortality at 100 days post transplantation by recording treatment-related adverse events",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Determine the incidence of grade 2-4 and 3-4 acute graft versus host disease at 100 days post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Determine incidence of chronic GVHD at 6 months and 1 year post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Estimate overall survival at 100 days and 1 year post transplantation by collecting survival information at those time points",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction\n* Age \\<= 65 years for previously treated and \\<= 75 years for previously treated patients\n* KPS \\>= 70%\n* Aplastic Anemia that meets the following criteria:\n\nPeripheral Blood (must fulfill 2 of 3):\n\n* \\<500 PMN/mm3\n* \\<20,000 platelets\n* absolute reticulocyte count \\<40,000/microL\n\nBone Marrow (must be either):\n\n* markedly hypocellular (\\<25% of normal cellularity)\n* moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above\n\nExclusion Criteria:\n\n* poor cardiac function (LVEF \\<40%)\n* poor pulmonary function (FEV1 \\& FVC \\<50% predicted)\n* poor liver function (bili \\>= 2mg/dL)\n* poor renal function (creatinine \\>= 2.0mg/dL or creatinine clearance \\<40mL/min)\n* prior allogeneic transplant",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "1 Year",
            "maximumAge": "75 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Melhem Solh, MD",
                    "role": "CONTACT",
                    "phone": "404-255-1930",
                    "email": "msolh@bmtga.com"
                },
                {
                    "name": "Stacey Brown",
                    "role": "CONTACT",
                    "phone": "404-851-8238",
                    "email": "stacey.brown@northside.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Melhem Solh, MD",
                    "affiliation": "Blood and Marrow Transplant Group of Georgia",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Blood and Marrow Transplant Group of Georgia",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30342",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melhem Solh, MD",
                            "role": "CONTACT",
                            "phone": "404-255-1930",
                            "email": "msolh@bmtga.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Northside Hospital",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30342",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melhem Solh, MD",
                            "role": "CONTACT",
                            "phone": "404-255-1930",
                            "email": "msolh@bmtga.com"
                        },
                        {
                            "name": "Stacey Brown",
                            "role": "CONTACT",
                            "phone": "404-851-8238",
                            "email": "stacey.brown@northside.com"
                        },
                        {
                            "name": "Scott Solomon, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "H. Kent Holland, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Asad Bashey, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Lawrence Morris, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Melhem Solh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "20018919",
                    "type": "BACKGROUND",
                    "citation": "Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L, Smith BD, Matsui WH, Goodman SN, Ambinder RF, Jones RJ. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-41. doi: 10.1182/blood-2009-06-225375. Epub 2009 Dec 16."
                },
                {
                    "pmid": "24319167",
                    "type": "RESULT",
                    "citation": "Socie G. Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities. Hematology Am Soc Hematol Educ Program. 2013;2013:82-6. doi: 10.1182/asheducation-2013.1.82."
                },
                {
                    "pmid": "24319166",
                    "type": "RESULT",
                    "citation": "Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013;2013(1):76-81. doi: 10.1182/asheducation-2013.1.76."
                },
                {
                    "pmid": "22517900",
                    "type": "RESULT",
                    "citation": "Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012 Aug 9;120(6):1185-96. doi: 10.1182/blood-2011-12-274019. Epub 2012 Apr 19."
                },
                {
                    "pmid": "26359881",
                    "type": "RESULT",
                    "citation": "Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, Solh M, Morris LE, Holland HK, Solomon SR. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. Biol Blood Marrow Transplant. 2016 Jan;22(1):125-33. doi: 10.1016/j.bbmt.2015.09.002. Epub 2015 Sep 7."
                },
                {
                    "pmid": "25797174",
                    "type": "RESULT",
                    "citation": "Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003. Epub 2015 Mar 19."
                },
                {
                    "pmid": "24842530",
                    "type": "RESULT",
                    "citation": "Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014 Aug;49(8):999-1008. doi: 10.1038/bmt.2014.62. Epub 2014 May 19."
                },
                {
                    "pmid": "2889870",
                    "type": "RESULT",
                    "citation": "Rozman C, Marin P, Nomdedeu B, Montserrat E. Criteria for severe aplastic anaemia. Lancet. 1987 Oct 24;2(8565):955-7. doi: 10.1016/s0140-6736(87)91432-2."
                },
                {
                    "pmid": "22796534",
                    "type": "RESULT",
                    "citation": "Atta EH, de Sousa AM, Schirmer MR, Bouzas LF, Nucci M, Abdelhay E. Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. Biol Blood Marrow Transplant. 2012 Dec;18(12):1876-82. doi: 10.1016/j.bbmt.2012.07.004. Epub 2012 Jul 11."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000000741",
                    "term": "Anemia, Aplastic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000080983",
                    "term": "Bone Marrow Failure Disorders"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "asFound": "Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4071",
                    "name": "Anemia, Aplastic",
                    "asFound": "Aplastic Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2241",
                    "name": "Bone Marrow Failure Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M13118",
                    "name": "Pancytopenia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T460",
                    "name": "Aplastic Anemia",
                    "asFound": "Aplastic Anemia",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "C000512542",
                    "term": "Thymoglobulin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M255823",
                    "name": "Thymoglobulin",
                    "asFound": "Necrotizing",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}